HighTower Advisors LLC Has $1.23 Million Stock Holdings in TransMedics Group, Inc. $TMDX

Key Points

• HighTower Advisors LLC increased its holdings in TransMedics Group, Inc. by 137.7% during the first quarter, owning approximately $1.23 million worth of shares after purchasing an additional 10,575 shares.
• Several analysts have given the stock an average rating of "Moderate Buy" with target prices ranging from $115.00 to $150.00, indicating confidence in the company's growth potential.
• TransMedics Group reported a quarterly earnings per share (EPS) of $0.92, significantly exceeding analyst expectations and reflecting a 37.7% year-over-year revenue increase.

HighTower Advisors LLC boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 137.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,257 shares of the company's stock after purchasing an additional 10,575 shares during the period. HighTower Advisors LLC owned about 0.05% of TransMedics Group worth $1,228,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in TMDX. NBC Securities Inc. bought a new position in TransMedics Group in the 1st quarter valued at approximately $25,000. Hager Investment Management Services LLC raised its stake in shares of TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after acquiring an additional 205 shares during the last quarter. CWM LLC raised its stake in shares of TransMedics Group by 20.1% during the first quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after acquiring an additional 155 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of TransMedics Group by 551.7% during the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock valued at $105,000 after acquiring an additional 1,324 shares during the last quarter. Finally, Sava Infond d.o.o. raised its stake in shares of TransMedics Group by 46.7% during the first quarter. Sava Infond d.o.o. now owns 2,200 shares of the company's stock valued at $148,000 after acquiring an additional 700 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

TransMedics Group Trading Down 1.5%

Shares of TMDX traded down $1.76 during trading hours on Friday, hitting $114.96. 665,581 shares of the stock were exchanged, compared to its average volume of 942,848. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $172.78. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The business has a 50-day moving average of $120.24 and a 200-day moving average of $103.29. The firm has a market capitalization of $3.92 billion, a P/E ratio of 59.57 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same period in the prior year, the company posted $0.35 earnings per share. TransMedics Group's revenue for the quarter was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. On average, research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analyst Weigh In

TMDX has been the subject of several analyst reports. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Monday, August 25th. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Oppenheimer raised their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Wall Street Zen downgraded shares of TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Morgan Stanley raised their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $123.00.

Insider Buying and Selling

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 7.00% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.